Haystack MRD® by Quest Diagnostics®

Haystack MRD® is an advanced tumor-informed minimal residual disease (MRD) test that detects ctDNA in blood with exceptional sensitivity and specificity.

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

One of our #ASCO26 posters (532) shows high concordance between ctDNA and ctHPV-DNA in HPV-driven oropharyngeal cancers, with ctDNA clearing faster than HPV in patients who were undergoing treatment. Learn more: https://t.co/SElQkOQxnC #ctDNA #MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Heading to #ASCO26? Visit our poster on ptDNA in gastroesophageal cancer to see how next-generation sequencing is being used in innovative ways to advance personalized care. May 30, 9:00 AM-12:00 PM, poster 84. https://t.co/KRs7Lzaw9U #ctDNA #MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Research collaborators are presenting new data at ASCO using Haystack MRD in 2 new disease types – gastric cancer and head and neck cancer.

Learn more about the abstracts being presented and meet Confidence, your Haystack Hero. https://t.co/VnWKtOQqli

#ASCO26 #ctDNA #MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Confidence changes how you move forward in cancer care. At #ASCO, see how Haystack MRD brings the clarity behind more confident clinical decisions. Visit the Quest Diagnostics booth 10109 to meet Confidence—the Haystack Hero for #ctDNA testing. Learn more: https://t.co/taagBmE8yl

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

See our poster presentation, “Real-world utilization of molecular residual disease testing in cancer care,” at #ONSCongress today: 11:25 AM–11:35 AM at Tower View Registration, Poster pavilion, Poster monitor 15. #ctDNA #MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Scientific session spotlight at the 2026 ONS Congress: “Real-world utilization of molecular residual disease testing in cancer care,” May 14 from 11:25 AM–11:35 AM at Tower View registration, Poster Pavilion, poster monitor 15. #ctDNA #MRD #ONSCongress

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

From clinical practice to clinical research, Haystack MRD® delivers exceptionally accurate ctDNA detection. See you at COA 2026 in Orlando. https://t.co/8Kl7tMkhLX #COA2026 #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Visit Quest Diagnostics® booth 808 at COA 2026 to learn how Haystack MRD® supports real-time treatment monitoring. https://t.co/L6oEBFlSVD #COA2026 #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

We're excited to share that Haystack MRD® by Quest Diagnostics® was featured on CBS News Baltimore! Watch the story here:
https://t.co/4sfOik6Ugz

#ctDNA #MRD #PrecisionOncology

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Biopharma teams: Haystack MRD® can support your oncology trials through ctDNA-guided patient enrichment and stratification. Let’s connect at COA 2026. https://t.co/Tz3424zx3w #COA2026 #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Oncology professionals—stop by Quest Diagnostics® booth 808 at the 2026 COA conference to explore ctDNA testing options with Haystack MRD®. https://t.co/rdgI3nTNhD #COA2026 #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Haystack MRD® helps clinicians detect recurrence, make treatment decisions, and monitor treatment response. Let’s connect at #COA2026—Quest Diagnostics® booth 808. Learn more: https://t.co/LLlwUigW3c

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

New collaboration with City of Hope on a multi-year research program to evaluate how Haystack MRD can help guide patient management in multiple cancers by detecting #minimalresidualdisease and identifying recurrence earlier
https://t.co/wjct3NwVem

#CityofHope #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Better insights can lead to better outcomes. See how Haystack MRD® by Quest Diagnostics® provides confidence and clarity to help guide treatment decisions. We’ll be at booth 118 at #SGOAM26. Learn more: https://t.co/lKrjXNnEq1 #ctDNA #MRD #HaystackMRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

We're excited to connect with the gynecologic oncology community at #SGOAM26. Find us at Quest Diagnostics® booth 118 to chat about ultrasensitive ctDNA testing. Learn more: https://t.co/n5620iipgm #ctDNA #MRD #HaystackMRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Identifying patients at high risk of relapse is critical. Learn how Haystack MRD® is helping clinicians do just that at Quest Diagnostics® booth 118 at #SGOAM26. Learn more: https://t.co/tERsFB6com #ctDNA #MRD #HaystackMRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Haystack MRD® offers exceptional accuracy and confidence in results. Let's discuss what that means for your practice at #SGOAM26. Find us at the Quest Diagnostics® booth 118. Learn more: Learn more: https://t.co/izGzxjmkb6 #ctDNA #MRD #HaystackMRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Planning your schedule for #SGOAM26? Make sure to add a visit to Quest Diagnostics® booth 118 to your list and learn how our exceptionally accurate ctDNA testing is being used in gynecological cancers. Learn more: https://t.co/WVknJHQLwa #ctDNA #MRD #HaystackMRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Heading to #SGOAM26 in San Juan? Visit the Quest Diagnostics® booth 118 to learn how Haystack MRD® delivers confidence through exceptionally accurate ctDNA detection. Learn more: https://t.co/aXCMWfhS01 #ctDNA #MRD #HaystackMRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

A New England Journal of Medicine study showed how ctDNA testing helped monitor treatment response in real time—without surgery, radiation, or chemo.

Watch Dr. Andrea Cercek discuss the results

👉 https://t.co/lkGLXphCAj

#CancerResearch #ctDNA #MRD #OncologyInnovation